Expression of long non-coding RNA SFTA1P in lung adenocarcinoma and its predictive value for prognosis

Menglei CHEN; Shuai YUAN; Meiyu ZHOU; Ying XIANG; Na WU; Long WU; Chengying LI; Bin XU; Yao ZHANG; Tongjian CAI; Xiangyu MA; Zubin YU; Li BAI; Jingyuan YANG; Yafei LI

doi:10.16016/j.1000-5404.202005271

您当前的位置：

首页 >

文章列表页 >

Expression of long non-coding RNA SFTA1P in lung adenocarcinoma and its predictive value for prognosis

Basic Medicine | 更新时间：2026-01-09

- Expression of long non-coding RNA SFTA1P in lung adenocarcinoma and its predictive value for prognosis
- Journal of Third Military Medical University Vol. 42, Issue 21, Pages: 2075-2080, 2215(2020)
- 作者机构：
  
  1.550000 贵阳，贵州医科大学公共卫生学院流行病学教研室
  2.400038重庆，陆军军医大学(第三军医大学)军事预防医学系军队流行病学教研室
  3.400037 重庆，陆军军医大学(第三军医大学)第二附属医院：胸外科，全军呼吸内科研究所，全军呼吸病研究重点实验室
  4.400037 重庆，陆军军医大学(第三军医大学)第二附属医院：全军呼吸内科研究所，全军呼吸病研究重点实验室
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(81871896);the General Program of National Natural Science Foundation of China(81672316)
- DOI：10.16016/j.1000-5404.202005271
  CLC： R181.23;R394.3;R734.2
- Received：09 May 2020，
  
  Revised：2020-08-13，
  
  Published：15 November 2020
- 稿件说明：
移动端阅览
Menglei CHEN, Shuai YUAN, Meiyu ZHOU, et al. Expression of long non-coding RNA SFTA1P in lung adenocarcinoma and its predictive value for prognosis[J]. Journal of Third Military Medical University, 2020, 42(21): 2075-2080, 2215.
DOI：

Menglei CHEN, Shuai YUAN, Meiyu ZHOU, et al. Expression of long non-coding RNA SFTA1P in lung adenocarcinoma and its predictive value for prognosis[J]. Journal of Third Military Medical University, 2020, 42(21): 2075-2080, 2215. DOI： 10.16016/j.1000-5404.202005271.

摘要

目的

探讨长链非编码RNA SFTA1P表达水平的变化与临床预后的关联，构建和评价SFTA1P用于肺腺癌患者预后预测的模型。

方法

实时荧光定量PCR检测SFTA1P在62对NSCLC组织以及相应的癌旁正常肺组织中的表达，分析SFTA1P表达水平的变化与临床预后的关联。在TCGA数据库中下载确诊为肺腺癌患者的数据集，提取所需的变量数据，整理了471例肺腺癌患者的临床参数信息和SFTA1P的表达量，利用单因素和多因素Cox比例风险回归模型筛选变量，基于最终预后预测模型构建列线图模型。预测模型进行内部验证采用Bootstrap重抽样法，采用一致性指数(concordance index，C-index)评价预测模型的区分度(discrimination)，校准曲线评价模型的校准度(calibration)。

结果

相比于癌旁正常肺组织(1.765±0.149)，SFTA1P在肺癌组织中的表达(0.692±0.103)显著下调(

＜0.05)。通过单因素和多因素Cox比例风险回归模型，共筛选出3个独立的临床变量与肺腺癌患者的生存率相关，分别是病理分期、放疗和SFTA1P表达量的水平。使用这3个变量，加上年龄变量共同构建列线图模型。在1年和3年生存率校准曲线中，其预测值与实际值显示了较好的一致性。列线图模型的一致性指数C-index为0.69，95%置信区间：0.63~0.75。

结论

长链非编码RNA SFTA1P的表达量可以作为肺腺癌的一个独立预后因素；采用上述4个独立变量构建的列线图模型可以预测肺腺癌患者的生存率。

Abstract

Objective

To investigate the expression of long non-coding (lnc) RNA SFTA1P in lung adenocarcinoma

and its association with clinical prognosis in order to construct and evaluate a prognostic prediction model based on SFTA1P.

Methods

Real-time fluorescence quantitative PCR was used to detect the expression of SFTA1P in 62 pairs of non-small-cell lung cancer (NSCLC) tissues and corresponding normal lung tissues adjacent to the cancer for the association between SFTA1P expression level and clinical prognosis. The data sets of patients diagnosed with lung adenocarcinoma were downloaded from TCGA database

the required variable data were extracted

and the clinical parameter information and SFTA1P expression of the 471 patients with lung adenocarcinoma were sorted out. Subsequently

variables were screened using univariate and multivariate Cox proportion risk regression models

and a nomogram model was constructed based on the final prognostic prediction model. For the internal validation of the prediction model

Bootstrap resampling method was adopted

and concordance index (C-index) and calibration curve were used respectively to evaluate the discrimination and calibration of the prediction model.

Results

The S

FTA1P expression was significantly decreased in the lung cancer tissues than the para-cancerous tissues (0.692±0.103

1.765±0.149

0.05). There were totally 3 selected independent clinical variables correlating to survival rates in the patients

that is

pathological stage

radiotherapy and SFTA1P expression. In the nomogram model

the calibration curves of 1-year and 3-year survival rates showed that the predicted values had good consistency with the actual values

with a C-index of 0.69 and 95% confidence interval of 0.63~0.75.

Conclusion

The expression of lnc RNA SFTA1P can be used as an independent prognostic factor for lung adenocarcinoma. The nomogram model constructed from the above independent variables (including age) can predict the survival rate of the patients.

关键词

Keywords

references

BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492.

SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1): 7-30. DOI:10.3322/caac.21442.

ETTINGER D S, AKERLEY W, BORGHAEI H, et al . Non-small cell lung cancer, version 2.2013[J ] . J Natl Compr Canc Netw, 2013, 11(6):645-653. DOI: 10.6004/jnccn.2013.0084.

WENDER R, FONTHAM E T, BARRERA E Jr, et al . American Cancer Society lung cancer screening guidelines[J ] . CA Cancer J Clin, 2013, 63(2): 107-117. DOI:10.3322/caac.21172.

CHEN Y, LI C, PAN Y, et al . The emerging role and promise of long noncoding RNAs in lung cancer treatment[J ] . Cell Physiol Biochem, 2016, 38(6): 2194-2206. DOI:10.1159/000445575.

CAMP R L, DOLLED-FILHART M, RIMM D L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization[J]. Clin Cancer Res, 2004, 10(21): 7252-7259. DOI:10.1158/1078-0432.CCR-04-0713.

韦尉东, 傅剑华, 林鹏, 等.非小细胞肺癌完全切除及综合治疗后预后预测模型的建立与评价[J].中华肿瘤杂志, 2008, 30(9): 672-675.

WEI W D, FU J H, LIN P, et al . Establishment and evaluation of a prognostic prediction model for patients after complete resection of non-small cell lung cancer and multidisciplinary therapy[J ] . Chin J Oncol, 2008, 30(9): 672-675.

HU Z G, HU K, LI W X, et al . Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion[J ] . PLoS ONE, 2019, 14(5): e0217007. DOI:10.1371/journal.pone.0217007.

DENG J Q, REN Z P, WEN J X, et al . Construction of a nomogram predicting the overall survival of patients with distantly metastatic non-small-cell lung cancer[J ] . Cancer Manag Res, 2018, 10: 6143-6156. DOI:10.2147/CMAR.S183878.

XIONG Y W, ZHANG X Y, LIN Z H, et al . SFTA1P, LINC00968, GATA6-AS1, TBX5-AS1, and FEZF1-AS1 are crucial long non-coding RNAs associated with the prognosis of lung squamous cell carcinoma[J ] . Oncol Lett, 2019, 18(4): 3985-3993. DOI:10.3892/ol.2019.10744.

ZHANG E B, YIN D D, SUN M, et al . P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression[J ] . Cell Death Dis, 2014, 5: e1243. DOI:10.1038/cddis.2014.201.

SUN M, LIU X H, LU K H, et al . EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition[J ] . Cell Death Dis, 2014, 5: e1298. DOI:10.1038/cddis.2014.256.

MA H W, MA T S, CHEN M, et al . The pseudogene- derived long non-coding RNA SFTA1P suppresses cell proliferation, migration, and invasion in gastric cancer[J ] . Biosci Rep, 2018, 38(2): BSR20171193. DOI:10.1042/BSR20171193.

周玫余, 袁帅, 向颖, 等.长链非编码RNA SFTA1P在非小细胞肺癌组织中的表达和细胞功能研究[J].中华疾病控制杂志, 2020, 24(3):341-347. DOI:10.16462/j.cnki.zhjbkz.2020.03.018.

ZHOU M Y, YUAN S, XIANG Y, et al . Expression and cellular function of long non-coding RNA SFTA1P in non-small cell lung cancer[J ] . Chin J Dis Control Prev, 2020, 24(3):341-347. DOI:10.16462/j.cnki.zhjbkz.2020.03.018.

ZHANG H, XIONG Y Q, XIA R, et al . The pseudogene-derived long noncoding RNA SFTA1P is down-regulated and suppresses cell migration and invasion in lung adenocarcinoma[J ] . Tumour Biol, 2017, 39(2): 1010428317691418. DOI:10.1177/1010428317691418.

ZHOU Z R, WANG W W, LI Y, et al . In-depth mining of clinical data: the construction of clinical prediction model with R[J ] . Ann Transl Med, 2019, 7(23): 796. DOI:10.21037/atm.2019.08.63.

PAN H, SHI X S, XIAO D K, et al . Nomogram prediction for the survivalof the patients with small cell lung cancer[J ] . J Thorac Dis, 2017, 9(3): 507-518. DOI:10.21037/jtd.2017.03.121.

IASONOS A, SCHRAG D, RAJ G V, et al . How to build and interpret a nomogram for cancer prognosis[J ] . J Clin Oncol, 2008, 26(8): 1364-1370. DOI:10.1200/JCO.2007.12.9791.

LIANG W H, ZHANG L, JIANG G N, et al . Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer[J ] . J Clin Oncol, 2015, 33(8): 861-869. DOI:10.1200/JCO.2014.56.6661.

WANG T, LU R, LAI S, et al . Development and validation of a nomogram prognostic model for patients with advanced non-small-cell lung cancer[J ] . Cancer Inform, 2019, 18: 1176935119837547. DOI:10.1177/1176935119837547.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Screening and validation of tsRNAs associated with lung adenocarcinoma

Expression and clinical significance of adenosine deaminase acting on RNA-1 in lung adenocarcinoma

Metastatic characteristics and prognosis of non-small cell lung cancer

Prognostic value of albumin in patients with de novo non-M3 acute myeloid leukemia

Serum CEA level is associated with efficacy and prognosis of EGFR-TKI treatment in non-small cell lung cancer: report of 88 cases

Related Author

LU Chunli

SHAN Yifan

XIE Weijia

XIA Tingting

XIANG Ying

WU Na

WU Long

BAI Li

Related Institution

Department of Epidemiology， Faculty of Military Preventive Medicine， Army Medical University （Third Military Medical University）， Chongqing, PLA Key Laboratory of Respiratory Diseases， Second Affiliated Hospital， Army Medical University （Third Military Medical University）

Institute of Respiratory Diseases, PLA Key Laboratory of Respiratory Diseases， Second Affiliated Hospital， Army Medical University （Third Military Medical University）

Cancer Center, the Second Affiliated Hospital of Chongqing Medical University

Cancer Institute, Second Affiliated Hospital, Army Medical University (Third Military Medical University)

Center for Hematology，First Affiliated Hospital，Army Medical University（Third Military Medical University）

⁰